NASDAQ:PMN Promis Neurosciences Q1 2026 Earnings Results & Report $3.87 -0.11 (-2.79%) As of 02:48 PM Eastern This is a fair market value price provided by Massive. Learn more. Promis Neurosciences missed analyst earnings expectations in its Q1 2026 results, released May 12, 2026. The company reported EPS of -$1.26 versus the -$1.06 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateMay 12, 2026TimeBefore Market OpensConference Call7:00 AM ET Promis Neurosciences EPS ResultsActual EPS-$1.26Consensus EPS -$1.06Beat/MissMissed by -$0.20One Year Ago EPSN/AEPS Beat Rate3 of last 7 quartersPromis Neurosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsPromis Neurosciences' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2026 Earnings ReportConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Promis Neurosciences Q1 2026 Earnings FAQ Did Promis Neurosciences beat earnings estimates for Q1 2026? Promis Neurosciences (NASDAQ:PMN) reported earnings of -$1.26 per share for Q1 2026, missing the consensus estimate of -$1.06. The report was announced on Tuesday, May 12, 2026. When is Promis Neurosciences' next earnings date? Promis Neurosciences' next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Promis Neurosciences on the company's earnings history page. Promis Neurosciences Earnings HeadlinesPromis Neurosciences (PMN) Expected to Announce Quarterly Earnings on ThursdayNovember 11 at 2:13 AM | americanbankingnews.comProMIS Neurosciences to Participate in Upcoming Conferences in NovemberNovember 5, 2026 | globenewswire.comI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.November 11 at 1:00 AM | Behind the Markets (Ad)Promis Neurosciences (NASDAQ:PMN) Stock Price Target Cut by Roth CapitalNovember 4, 2026 | americanbankingnews.comProMIS Neurosciences to Report Third Quarter 2026 Financial Results and Business Update on November 12, 2026November 3, 2026 | globenewswire.comProMIS Names Commercial Chief; PMN310 Data Due Q1 2027; Stock DownOctober 6, 2026 | rttnews.comSee More Promis Neurosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Promis Neurosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Promis Neurosciences and other key companies, straight to your email. Email Address About Promis NeurosciencesPromis Neurosciences (NASDAQ:PMN) Inc. (NASDAQ: PMN) is a clinical-stage biotechnology company developing precision medicines for neurodegenerative diseases. The company’s research focuses on misfolded proteins, which can form toxic structures associated with conditions such as Alzheimer’s disease, amyotrophic lateral sclerosis and other neurological disorders. ProMIS uses its proprietary target-discovery platform to identify disease-specific toxic protein conformations and develop antibodies intended to selectively bind and neutralize them while avoiding healthy forms of the same proteins. Its lead product candidate, PMN310, is an investigational antibody designed to target toxic soluble amyloid-beta oligomers implicated in Alzheimer’s disease. The company has also pursued programs directed at misfolded proteins associated with other neurodegenerative conditions. ProMIS Neurosciences is based in Toronto, Canada, and conducts research and development activities through North American operations and collaborations. The company was founded to advance antibody-based therapies for diseases that have historically been difficult to treat. Its leadership has included Chief Executive Officer Neil McFarlane and co-founder and Chief Scientific Officer Dr. Neil Cashman, a researcher known for work on protein misfolding and neurodegenerative disease.View Promis Neurosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Can Constellation Energy's Contracts Power a Stock Rebound?IonQ Raised the Bar, But 3 Quantum Rivals Face Tough QuestionsAmazon's Rally Is Outpacing Big Tech, But Can AWS Justify the AI Spending?Aehr Test Systems Notches Another Post-Earnings Win as Sales Triple on AI DemandThe Trade Desk Beats on Revenue, But the Fine Print MattersWhy Kinder Morgan's Chairman Just Bought $15 Million in StockA $4 Billion Jolt: NRG Energy Powers Data Center Ambitions Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
